Table 1.
Baseline characteristics of patients with PCNSL (n = 48)
| Variable | n (%miss.) | Overall (n = 48) | No progression or death during follow‐up (n = 16) | Progression or death during follow‐up (n = 32) | P* |
|---|---|---|---|---|---|
| Demographics | |||||
| Female gender | 48(0%) | 17 (35%) | 7 (44%) | 10 (31%) | .393 |
| BMI at diagnosis (kg/m2) | 48(0%) | 26.7 [23.2‐28.4] | 26.1 [22.7‐29.6] | 26.9 [24.0‐28.4] | .877 |
| Age at diagnosis (years) | 48 (0%) | 60 [53–69] | 58 [49‐68] | 64 [57‐74] | .133 |
| ECOG (points) | 48 (0%) | 1 [1–2] | 1 [1‐2] | 2 [1‐3] | .361 |
| Tumor characteristics | |||||
| Clinical stage | 48 (0%) | — | — | — | .667 |
| I or II | — | 47 (98%) | 16 (100%) | 31 (97%) | — |
| III or IV | — | 1 (2%) | 0 (0%) | 1 (3%) | — |
| DLBCL “cell of origin” | 42(12%) | — | — | — | .608 |
| Activated B‐center (ABC) | — | 39 (93%) | 10 (91%) | 29 (94%) | — |
| Germinal center (GC) | — | 3 (7%) | 1 (9%) | 2 (6%) | — |
| DEL biology | 48 (0%) | — | — | — | <.0001 |
| 0 points | — | 12 (24%) | 9 (56%) | 3 (9%) | — |
| 1 point | — | 18 (38%) | 6 (38%) | 12 (38%) | — |
| 2 points | — | 18 (38%) | 1 (6%) | 17 (53%) | — |
| Involvement of deep brain structures | 48 (0%) | 29 (60%) | 11 (69%) | 18 (56%) | .404 |
| Risk stratification systems | |||||
| IPI (points) | 48 (0%) | 1 [1–2] | 1 [1–2] | 1 [1–2] | .174 |
| R‐IPI (points) | 48 (0%) | 1 [1–2] | 1 [1–2] | 1 [1–2] | .174 |
| NCCN‐IPI (points) | 48 (0%) | 3 [3–4] | 3 [2‐4] | 4 [3‐4] | .098 |
| MSKCC (points) | 48 (0%) | 1 [1–2] | 1 [1‐2] | 2 [1‐2] | .132 |
| IELSGa (points) | 48 (0%) | 1 [1–2] | 1 [1–2] | 1 [1‐2] | .638 |
Note: Distribution overall and by PFS status. Data are reported as medians [25th‐75th percentile] or as absolute counts (%). n (%miss.) reports the number of patients with fully observed data for the respective variable (% missing). *P‐values are either from rank‐sum tests, χ2‐tests, or Fisher's exact tests, as appropriate.
Abbreviations: BMI, body mass index; DEL, double expressor lymphoma; DLBCL, diffuse large B‐cell lymphoma; ECOG, Eastern Cooperative Oncology Group performance status; IELSG, International Extranodal Lymphoma Study Group risk score for PCNSL outcomes (without cerebrospinal fluid); IPI, International Prognostic Index; MSKCC, Memorial Sloan Kettering Cancer Centre risk score for PCNSL outcomes; NCCN‐IPI, National Comprehensive Cancer Network International Prognostic Index; R‐IPI, Revised International Prognostic Index.
The IELSG score is calculated without cerebrospinal fluid.